Just Out on The Lancet Oncology The AtTEnd trial :A multicentre, double-blind, phase 3 study investigating the addition of atezolizumab, an immune checkpoint inhibitor, to standard chemotherapy (carboplatin and paclitaxel) in patients with advanced or recurrent #EndometrialCancer

How To Show Up For Yourself:

Loving every second of the 2nd week of inpatient lymphoma rotation at Memorial Sloan Kettering Cancer Center. Learning so much, and seeing such rare pathologies has been so enlightening. And all the TLS monitoring too 🤣

Fun fact to share from this rotation which I was unaware of: filgrastim/peg-filgrastim should not be used in patients with sickle cell disease (consideration came up for neutropenic fever in this case), as it serves as another form of stressor which can precipitate pain crisis!

It truly breaks my heart to see patients in my clinic who come to the office hoping for a “cure” when there isn’t one. I know I’m not saying something that hasn’t been said before, but we need to do so so much more for patients with pancreatic cancer. This cancer sucks so much!

Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe with initial intracranial control results that appear encouraging. ja.ma/4fAaPDY Kamran Ahmed Moffitt Cancer Center

TROPHY-U-01 Cohort 2: Sacituzumab Govitecan achieved an ORR of 32% in cisplatin-ineligible metastatic urothelial cancer. Median PFS was 5.6 months. Main toxicities: neutropenia (34%), anemia (24%), and diarrhea (16%). #cancer #oncology OncoAlert Scott Tagawa Cora Sternberg

Summary of the FDA-approved tumor agnostic drugs #esmo24 #precisionmedicine

ADCs are among the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved and >200 in active development. Here’s 10 facts to know to prepare for the rise of ADCs🧵

Cancer Chemotherapy Cancer Cell

Adjuvant IO trials in muscle-invasive urothelial carcinoma: IMvigor010: Atezo DFS HR 0.89, OS HR 0.85. CheckMate 274: Nivo DFS HR 0.71, OS HR 0.76. AMBASSADOR: Pembro DFS HR 0.73, OS HR 0.98. #oncology #cancer #urothelialcarcinoma OncoAlert Matt Galsky Tom Powles Andrea Apolo, M.D.

Cancer statistics- 2025 👀 Some 🫁 cancer observations: 1. Continued nice decrease in LC incidence/death rates 2. BUT probably 1st time in history of cancer stats- more cases in women than men 3. AND finally we no longer can say - “lung cancer causes more deaths than

When you’re watching your Lymphoma attending casually drop ASH updates during your heme elective at the VA! Perfect timing!

Now available on pubmed! Results of the zenocutuzumab (Bizengri) basket trial in NRG1 fusion + solid tumors. This trial led to recent FDA approval in lung and pancreatic cancer. RNA seq is critical to identify these fusions. 🧬NEJM pubmed.ncbi.nlm.nih.gov/39908431/

Learned a lot from Dr. Salles during my elective in Lymphoma clinics over the past month. I got to see very interesting patients, with even more exciting treatment plans! Memorial Sloan Kettering Cancer Center truly harbors the most insightful teachers. Thankful to Efrat Luttwak for this rotation!!!

Establishing nivo/AVD in elderly patients with classic Hodgkin’s lymphoma would transform the care of patients suffering from cHL above the age of 60 years! Congratulations Pallawi Torka Paola Ghione MD, MSEpi Santosh Vardhana!! So blessed to have worked with you!

BREAKING from NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.

De-escalation of ICI therapy in NSCLC through either a) lower dosing regiments, b) decreased frequency of administration or c) fixed duration of therapy. The economic benefits would revolutionize antibody use! Such a valuable read Jordi Remon and Benjamin Besse!

Houssein Safa, MD Excited to be applying to #HemeOnc fellowship this cycle! I’m Dedipya Bhamidipati—IM chief resident! Excited to connect with programs & applicants! 📄 AAMC ID: 15373622 #MedTwitter #Fellowship2026 #Oncology #Hematology